一个随机,双盲,安慰剂控制的试验试验与Sirona的开放式扩展,一种用于减肥的水凝
James P Byrne1, Elanor C Hinton2,3, Asif Malik Humayun4
1NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
Obesity (Silver Spring, Md.)
|October 15, 2025
概括
新型胃保持聚合物Sirona在体重管理方面表现出良好的耐受性和安全性. 它在12周的试点试验中显著降低了体重和饮食摄入量.
科学领域:
- 肥胖研究的研究.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一种复杂的代谢障碍,需要有效的管理策略.
- 新型胃保持性聚合物为非药物管理的体重管理提供了潜力.
- 西罗纳是一种双网聚合物,旨在持续释放和胃保留.
研究的目的:
- 调查Sirona用于体重管理的安全性和耐受性.
- 评估Sirona在减少体重和饮食摄入量方面的初步疗效.
- 评估Sirona作为治疗肥胖的非药物干预措施的可行性.
主要方法:
- 一个为期12周的随机,双盲,安慰剂控制的试验试验,并进行了为期12周的开放式延长.
- 体重指数为30-40公斤/平方米的参与者接受了Sirona或安慰剂,比例为3:1.
- 主要终点包括可行性,耐受性和安全性;次要终点是减肥和饮食摄入量.
主要成果:
- 西罗纳耐受性很好,最常见的是轻微的胃肠道副作用 (主要是恶心).
- 与安慰剂相比,接受Sirona的参与者在12周后的总体体重减轻比例显著增加 (3.9%对1.0%).
- 在开放式扩展中,体重减轻继续,而Sirona治疗导致了饮食摄入量显著减少.
结论:
- 锡罗纳是一种安全且耐受性良好的胃保持性聚合物,用于体重管理.
- 观察到的减肥和减少饮食摄入量表明,Sirona作为治疗肥胖的非药物治疗的潜力.
- 需要进一步的研究来证实Sirona在较大人群中的长期疗效和安全性.
相关概念视频
Drug Dosing: Obese Patients
222
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
222
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K


